ArticleJournal for immunotherapy of cancer2021

Human leukocyte antigen class II-based immune risk model for recurrence evaluation in stage I-III small cell lung cancer.

Peixin Chen et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.